Q-omics provides the consensus-scored SEC61A2 profile across patient tissues and cancer cell-line models. SEC61A2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SEC61A2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SEC61A2 RNA expression shows 21,215 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where SEC61A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC61A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC61A2 survival associations across molecular data types. SEC61A2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC61A2 RNA expression–survival associations across cancer types. High SEC61A2 expression shows unfavorable associations in KIRC, KICH, ACC, KIRP and UVM, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SEC61A2 RNA expression.
This table summarizes SEC61A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SEC61A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC61A2 shows higher tumor expression in HNSC, COAD, BLCA, LUSC, STAD and LUAD. The HNSC box plot shows higher SEC61A2 RNA expression in tumor versus normal tissue (log2 FC = +0.813, t-test p < 0.001).
This table shows molecular features associated with SEC61A2 in patient tissues and cancer cell lines. In patient samples, SEC61A2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC61A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
